1-3 of 3
Filip Beeldens
Close
Sort by
Journal Articles

Phase II–III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial

Sergio Amadori, Stefan Suciu, Dominik Selleslag, Giuliana Alimena, Liliana Baila, Vittorio Rizzoli, Giuseppe Rossi, Gianluca Gaidano, Domenico Magro, Giuseppe Torelli, Petra Muus, Adriano Venditti, Emma Cacciola, Francesco Lauria, Filip Beeldens, Marco Vignetti, Theo de Witte
Journal: Blood
Blood (2008) 112 (11): 762.
https://doi.org/10.1182/blood.V112.11.762.762
Published: 2008
Journal Articles

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups

Pierre WijerMans, Stefan Suciu, Liliana Baila, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Helmut Salih, Filip Beeldens, Petra Muus, Theo de Witte, Michael Lübbert, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 226.
https://doi.org/10.1182/blood.V112.11.226.226
Published: 2008
Journal Articles

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

Clinical Trials & Observations
Sergio Amadori, Stefan Suciu, Ulrich Jehn, Roberto Stasi, Xavier Thomas, Jean-Pierre Marie, Petra Muus, Francois Lefrère, Zwi Berneman, George Fillet, Claudio Denzlinger, Roel Willemze, Pietro Leoni, Giuseppe Leone, Marco Casini, Francesco Ricciuti, Marco Vignetti, Filip Beeldens, Franco Mandelli, Theo De Witte, for the EORTC/GIMEMA Leukemia Groups
Journal: Blood
Blood (2005) 106 (1): 27–34.
https://doi.org/10.1182/blood-2004-09-3728
Published: 2005